Loading...

DNLI DENALI THERAPEUTICS INC Product Launches 8-K Filing

DNL

DNL

DENALI THERAPEUTICS INC

(DNLI)

2026 8-K

Funding Received

FDA Approval Granted

Financial Results Announced

Public Offering Announcement

Investor Day Update

Royalty Agreement Signed

Financial Results

FDA Approval Delay

Clinical Trials

Financial Statements

Product Approval

Equity Agreement

Bylaw Amendments

Q3 Financial Results

Study Discontinued

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Private Placement

Phase 2 HIMALAYA Study Results

Earnings Reports

Amendment to Agreement

Financial Results Announcement

Clinical Development Progra...

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

External Links:

Denali Therapeutics Inc. announced on March 25, 2026, that the FDA approved AVLAYAH™ (tividenofusp alfa) for treating neurologic symptoms in pediatric patients with Hunter syndrome weighing at least 5 kg. This development is significant for the company as it expands their treatment options in a niche area.

AI Assistant

DENALI THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.